<DOC>
	<DOCNO>NCT00099645</DOCNO>
	<brief_summary>The purpose study determine anti-HIV activity safety 3 different dos mifepristone ( also know VGX-410 RU486 ) HIV infected people . Hypothesis : Mifepristone generally safe ( serious adverse effect ) well tolerate .</brief_summary>
	<brief_title>Anti-HIV Activity Safety 3 Different Doses Mifepristone HIV Infected People</brief_title>
	<detailed_description>Mifepristone potent anti-glucocorticoid compound effectively inhibit replication laboratory clinical HIV isolate vitro . This study evaluate anti-HIV activity safety 3 different dos mifepristone HIV infected people . This study last approximately 2 month . Participants randomly assign one 4 study arm , receive either mifepristone placebo daily 28 day . Arm A participant receive one three dos placebo ; Arm B participant receive 75 mg mifepristone ; Arm C participant receive 150 mg mifepristone ; Arm D participant receive 225 mg mifepristone . A thorough neck thyroid examination perform within 30 day prior study entry . Blood collection vital sign measurement occur study entry Days 3 , 7 , 14 , 21 , 28 , 56 . Urine collection pill count also do study visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>HIV1 infect CD4 count 350 cells/mm3 within 90 day prior study entry HIV1 viral load 2000 copies/ml within 90 day prior study entry Willing use acceptable form contraception study 30 day stop study medication If currently take precautionary concomitant medication , must stable dos 8 week prior study entry plan change medication dos duration study Body weight least 40 kg ( 88 lb ) within 90 day prior study entry Antiretroviral treatment ( ART ) within 16 week prior study entry , intend start ART within 60 day entry Adrenal disorder History autoimmune endocrine disease self family History active hepatitis B C Current treatment hepatitis B C Moderate severe liver disease Blood disorder current anticoagulant therapy Prior pituitary tumor , surgery , radiation treatment , pituitary failure Moderate large goiter thyroid nodule Diabetes mellitus Unusual uterine bleed within 12 month prior study entry Current hormonal contraception intrauterine ( IUD ) use , include progesteronecontaining vaginal ring Pregnancy within 90 day prior study entry Breastfeeding Drugs act inhibitor inducer metabolism cytochrome P450 3A4 Systemic corticosteroid hormonal agent within 90 day prior study entry Any immunomodulator , HIV vaccine , investigational therapy within 90 day prior study entry Any vaccination within 30 day prior study entry Systemic cytotoxic chemotherapy within 90 day prior study entry History allergy mifepristone study formulation Current drug alcohol abuse , opinion investigator , may interfere study Any condition may interfere participant evaluation study Serious illness require systemic treatment hospitalization . Patients complete therapy clinically stable therapy least 14 day prior study entry exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Mifepristone</keyword>
	<keyword>Mifeprex</keyword>
	<keyword>RU486</keyword>
	<keyword>VGX-410</keyword>
	<keyword>Abortion Pill</keyword>
	<keyword>Investigational Drug</keyword>
</DOC>